Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

707 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Pharmacokinetic/Pharmacodynamic Modelling to Describe the Cholesterol Lowering Effect of Rosuvastatin in People Living with HIV.
Courlet P, Guidi M, Alves Saldanha S, Stader F, Traytel A, Cavassini M, Stoeckle M, Buclin T, Marzolini C, Decosterd LA, Csajka C; and the Swiss HIV Cohort Study. Courlet P, et al. Among authors: cavassini m. Clin Pharmacokinet. 2021 Mar;60(3):379-390. doi: 10.1007/s40262-020-00946-3. Epub 2020 Oct 29. Clin Pharmacokinet. 2021. PMID: 33124006 Free PMC article.
In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function.
di Iulio J, Fayet A, Arab-Alameddine M, Rotger M, Lubomirov R, Cavassini M, Furrer H, Günthard HF, Colombo S, Csajka C, Eap CB, Decosterd LA, Telenti A; Swiss HIV Cohort Study. di Iulio J, et al. Among authors: cavassini m. Pharmacogenet Genomics. 2009 Apr;19(4):300-9. doi: 10.1097/FPC.0b013e328328d577. Pharmacogenet Genomics. 2009. PMID: 19238117
Implementation of raltegravir in routine clinical practice: selection criteria for choosing this drug, virologic response rates, and characteristics of failures.
Scherrer AU, von Wyl V, Fux CA, Opravil M, Bucher HC, Fayet A, Decosterd LA, Hirschel B, Khanlari B, Yerly S, Klimkait T, Furrer H, Ledergerber B, Günthard HF; Swiss HIV Cohort Study. Scherrer AU, et al. J Acquir Immune Defic Syndr. 2010 Apr 1;53(4):464-71. doi: 10.1097/QAI.0b013e3181bca4ec. J Acquir Immune Defic Syndr. 2010. PMID: 19841590
ADME pharmacogenetics: investigation of the pharmacokinetics of the antiretroviral agent lopinavir coformulated with ritonavir.
Lubomirov R, di Iulio J, Fayet A, Colombo S, Martinez R, Marzolini C, Furrer H, Vernazza P, Calmy A, Cavassini M, Ledergerber B, Rentsch K, Descombes P, Buclin T, Decosterd LA, Csajka C, Telenti A; Swiss HIV Cohort Study. Lubomirov R, et al. Among authors: cavassini m. Pharmacogenet Genomics. 2010 Apr;20(4):217-30. doi: 10.1097/FPC.0b013e328336eee4. Pharmacogenet Genomics. 2010. PMID: 20139798
Successful efavirenz dose reduction guided by therapeutic drug monitoring.
Fayet Mello A, Buclin T, Decosterd LA, Delhumeau C, di Iulio J, Fleurent A, Schneider MP, Cavassini M, Telenti A, Hirschel B, Calmy A. Fayet Mello A, et al. Among authors: cavassini m. Antivir Ther. 2011;16(2):189-97. doi: 10.3851/IMP1742. Antivir Ther. 2011. PMID: 21447868 Clinical Trial.
Cell disposition of raltegravir and newer antiretrovirals in HIV-infected patients: high inter-individual variability in raltegravir cellular penetration.
Fayet Mello A, Buclin T, Franc C, Colombo S, Cruchon S, Guignard N, Biollaz J, Telenti A, Decosterd LA, Cavassini M. Fayet Mello A, et al. Among authors: cavassini m. J Antimicrob Chemother. 2011 Jul;66(7):1573-81. doi: 10.1093/jac/dkr151. Epub 2011 Apr 19. J Antimicrob Chemother. 2011. PMID: 21508009 Clinical Trial.
Ageing with HIV: medication use and risk for potential drug-drug interactions.
Marzolini C, Back D, Weber R, Furrer H, Cavassini M, Calmy A, Vernazza P, Bernasconi E, Khoo S, Battegay M, Elzi L; Swiss HIV Cohort Study Members. Marzolini C, et al. Among authors: cavassini m. J Antimicrob Chemother. 2011 Sep;66(9):2107-11. doi: 10.1093/jac/dkr248. Epub 2011 Jun 16. J Antimicrob Chemother. 2011. PMID: 21680580 Free article.
707 results